• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将时变的餐后内脏血流增加纳入到 PBPK 模型中,以预测食物对口服高提取药物的药代动力学的影响。

Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs.

机构信息

Simcyp (a Certara Company), Blades Enterprise Centre, John Street, S2 4SU, Sheffield, UK.

出版信息

AAPS J. 2017 Jul;19(4):1205-1217. doi: 10.1208/s12248-017-0099-z. Epub 2017 May 19.

DOI:10.1208/s12248-017-0099-z
PMID:28526963
Abstract

Following a meal, a transient increase in splanchnic blood flow occurs that can result in increased exposure to orally administered high-extraction drugs. Typically, physiologically based pharmacokinetic (PBPK) models have incorporated this increase in blood flow as a time-invariant fed/fasted ratio, but this approach is unable to explain the extent of increased drug exposure. A model for the time-varying increase in splanchnic blood flow following a moderate- to high-calorie meal (TV-Q ) was developed to describe the observed data for healthy individuals. This was integrated within a PBPK model and used to predict the contribution of increased splanchnic blood flow to the observed food effect for two orally administered high-extraction drugs, propranolol and ibrutinib. The model predicted geometric mean fed/fasted AUC and C ratios of 1.24 and 1.29 for propranolol, which were within the range of published values (within 1.0-1.8-fold of values from eight clinical studies). For ibrutinib, the predicted geometric mean fed/fasted AUC and C ratios were 2.0 and 1.84, respectively, which was within 1.1-fold of the reported fed/fasted AUC ratio but underestimated the reported C ratio by up to 1.9-fold. For both drugs, the interindividual variability in fed/fasted AUC and C ratios was underpredicted. This suggests that the postprandial change in splanchnic blood flow is a major mechanism of the food effect for propranolol and ibrutinib but is insufficient to fully explain the observations. The proposed model is anticipated to improve the prediction of food effect for high-extraction drugs, but should be considered with other mechanisms.

摘要

进食后,内脏血流会出现短暂增加,这可能导致口服高提取药物的暴露增加。通常,基于生理学的药代动力学(PBPK)模型将这种血流增加作为时不变的进食/禁食比值进行整合,但这种方法无法解释药物暴露增加的程度。开发了一种用于描述健康个体中等至高卡路里餐后内脏血流时变增加的模型(TV-Q)。该模型被整合到 PBPK 模型中,用于预测两种口服高提取药物(普萘洛尔和依鲁替尼)增加的内脏血流对观察到的食物效应的贡献。该模型预测普萘洛尔的几何平均进食/禁食 AUC 和 C 的比值为 1.24 和 1.29,在已发表值的范围内(八个临床研究值的 1.0-1.8 倍)。对于依鲁替尼,预测的几何平均进食/禁食 AUC 和 C 的比值分别为 2.0 和 1.84,分别在报告的进食/禁食 AUC 比值的 1.1 倍内,但 C 的比值低估了 1.9 倍。对于这两种药物,进食/禁食 AUC 和 C 的比值的个体间变异性被低估。这表明,内脏血流的餐后变化是普萘洛尔和依鲁替尼食物效应的主要机制,但不足以完全解释观察结果。预计该模型将改善高提取药物的食物效应预测,但应与其他机制一起考虑。

相似文献

1
Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs.将时变的餐后内脏血流增加纳入到 PBPK 模型中,以预测食物对口服高提取药物的药代动力学的影响。
AAPS J. 2017 Jul;19(4):1205-1217. doi: 10.1208/s12248-017-0099-z. Epub 2017 May 19.
2
Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.健康男性志愿者中每日 1 次给予盐酸普拉克索控释片的药代动力学:3 项研究。
Clin Ther. 2009 Nov;31(11):2698-711. doi: 10.1016/j.clinthera.2009.10.018.
3
Biliary Excretion-Mediated Food Effects and Prediction.胆汁排泄介导的食物效应及其预测。
AAPS J. 2020 Sep 27;22(6):124. doi: 10.1208/s12248-020-00509-1.
4
Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.基于生物相关溶解试验结合生理基于药代动力学模型预测塞来昔布的食物对吸收的影响。
Eur J Pharm Biopharm. 2009 Sep;73(1):107-14. doi: 10.1016/j.ejpb.2009.05.009. Epub 2009 May 22.
5
Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.空腹和进食条件下 105 毫克非诺贝特酸片与 145 毫克非诺贝特片的单次给药生物等效性:两项 I 期、开放标签、单次给药、随机、交叉临床试验报告。
Clin Ther. 2011 Jun;33(6):766-75. doi: 10.1016/j.clinthera.2011.05.047.
6
Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.在禁食状态下,小肠中的沉淀可能在难溶性弱碱性药物的体内性能中发挥更重要的作用:以奈非那韦为例。
Eur J Pharm Biopharm. 2011 Oct;79(2):349-56. doi: 10.1016/j.ejpb.2011.04.005. Epub 2011 Apr 18.
7
Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.盐酸沙丙蝶呤片完整片和溶解片的相对生物利用度及食物的影响:一项在健康成年人中开展的随机、开放标签、交叉研究。
Clin Ther. 2010 Feb;32(2):338-46. doi: 10.1016/j.clinthera.2010.02.012.
8
Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA.使用基于生理的药代动力学(PBPK)模型预测CYP3A诱导剂对底物药物药代动力学的影响:对提交给美国食品药品监督管理局(FDA)的PBPK资料的分析
Clin Pharmacokinet. 2016 Apr;55(4):475-83. doi: 10.1007/s40262-015-0330-y.
9
Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.半机械论生理基于药代动力学模型对临床格列本脲药代动力学和药物相互作用的研究。
Eur J Pharm Sci. 2013 Aug 16;49(5):819-28. doi: 10.1016/j.ejps.2013.06.009. Epub 2013 Jun 24.
10
Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.食物和抗酸剂对健康成年受试者中艾曲泊帕药代动力学的影响:两项单剂量、开放标签、随机序列、交叉研究。
Clin Ther. 2009 Apr;31(4):764-76. doi: 10.1016/j.clinthera.2009.04.010.

引用本文的文献

1
Feed status and skin injury modulate immunopathology, global gene expression, and survival in channel catfish during virulent infection.饲料状态和皮肤损伤在强毒感染期间调节斑点叉尾鮰的免疫病理学、整体基因表达及存活情况。
Front Immunol. 2025 Jul 22;16:1642531. doi: 10.3389/fimmu.2025.1642531. eCollection 2025.
2
Development, validation, and clinical application of LC-MS/MS method for simultaneous determination of ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, and their active metabolites in patients with B-cell lymphoma.用于同时测定B细胞淋巴瘤患者中伊布替尼、泽布替尼、奥雷巴替尼、阿卡拉布替尼及其活性代谢物的液相色谱-串联质谱法的开发、验证及临床应用
Anal Bioanal Chem. 2025 Feb;417(4):821-834. doi: 10.1007/s00216-024-05701-2. Epub 2024 Dec 19.
3

本文引用的文献

1
Mechanistic investigation of the negative food effect of modified release zolpidem.缓释唑吡坦负性食物效应的机制研究
Eur J Pharm Sci. 2017 May 1;102:284-298. doi: 10.1016/j.ejps.2017.03.011. Epub 2017 Mar 10.
2
Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.基于 CYP3A4 代谢酶诱导剂相互作用潜力的伊布替尼给药策略:应用生理药代动力学模型。
Clin Pharmacol Ther. 2016 Nov;100(5):548-557. doi: 10.1002/cpt.419. Epub 2016 Aug 27.
3
Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance.
A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator.用于 Simcyp 模拟器中基于生理的药代动力学建模的群体文件开发指南。
CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1429-1447. doi: 10.1002/psp4.13202. Epub 2024 Jul 18.
4
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs.生理药代动力学模型在小分子靶向抗癌药物研究中的应用。
Cancer Chemother Pharmacol. 2023 Oct;92(4):253-270. doi: 10.1007/s00280-023-04566-z. Epub 2023 Jul 19.
5
A Physiologically-Based Pharmacokinetic Model for Cannabidiol in Healthy Adults, Hepatically-Impaired Adults, and Children.在健康成年人、肝损伤成年人和儿童中,大麻二酚的基于生理的药代动力学模型。
Drug Metab Dispos. 2023 Jun;51(6):743-752. doi: 10.1124/dmd.122.001128. Epub 2023 Mar 27.
6
Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals.基于生理学的药代动力学模型识别肥胖个体中影响药代动力学的生理和药物参数。
Clin Pharmacokinet. 2023 Feb;62(2):277-295. doi: 10.1007/s40262-022-01194-3. Epub 2022 Dec 26.
7
Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.克罗恩病的生物利用度和药代动力学改变:捕获 PBPK 系统参数以帮助预测口服药物的命运。
Clin Pharmacokinet. 2022 Oct;61(10):1365-1392. doi: 10.1007/s40262-022-01169-4. Epub 2022 Sep 3.
8
PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease.COVID-19合并肝病患者地塞米松的生理药代动力学建模
Front Pharmacol. 2022 Jan 28;13:814134. doi: 10.3389/fphar.2022.814134. eCollection 2022.
9
Meta-Analysis of Food Effect on Oral Absorption of Efflux Transporter Substrate Drugs: Does Delayed Gastric Emptying Influence Drug Transport Kinetics?食物对外排转运体底物药物口服吸收影响的荟萃分析:胃排空延迟是否会影响药物转运动力学?
Pharmaceutics. 2021 Jul 7;13(7):1035. doi: 10.3390/pharmaceutics13071035.
10
Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.开发和评估普萘洛尔基于生理学的药代动力学药物-疾病模型,以建议肝硬化患者的模型指导剂量。
Drug Des Devel Ther. 2021 Mar 17;15:1195-1211. doi: 10.2147/DDDT.S297981. eCollection 2021.
基于生理的药代动力学(PBPK)模型的开发与应用的最新进展:从学术好奇到监管认可的转变
Curr Pharmacol Rep. 2016;2(3):161-169. doi: 10.1007/s40495-016-0059-9. Epub 2016 Apr 14.
4
Differences in Food Effects for 2 Weak Bases With Similar BCS Drug-Related Properties: What Is Happening in the Intestinal Lumen?两种具有相似生物药剂学分类系统(BCS)药物相关性质的弱碱的食物效应差异:肠腔内发生了什么?
J Pharm Sci. 2016 Sep;105(9):2712-2722. doi: 10.1016/j.xphs.2015.11.033. Epub 2016 Feb 23.
5
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.食物对健康受试者和慢性淋巴细胞白血病患者口服依鲁替尼药代动力学的影响。
Cancer Chemother Pharmacol. 2015 May;75(5):907-16. doi: 10.1007/s00280-015-2708-9. Epub 2015 Feb 28.
6
Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect.基于生理的吸收模型在低溶解度、低渗透性弱碱制剂开发中的应用:食物效应的机制研究
AAPS PharmSciTech. 2014 Apr;15(2):400-6. doi: 10.1208/s12249-014-0075-1. Epub 2014 Jan 17.
7
Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.使用基于生理学的ADAM模型从体外数据对特定制剂的食物效应及其人群变异性进行定量预测:以BCS/BDDCS II类药物硝苯地平为例的研究
Eur J Pharm Sci. 2014 Jun 16;57:240-9. doi: 10.1016/j.ejps.2013.09.006. Epub 2013 Sep 21.
8
Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.应用计算机模拟、体外和临床前体内数据对 BCS/BDDCS 分类化合物进行实际食物效应评估的案例研究。
AAPS J. 2013 Jan;15(1):143-58. doi: 10.1208/s12248-012-9419-5. Epub 2012 Nov 10.
9
Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.重组表达和人肝微粒体细胞色素 P450 2C9 的单位酶催化活性是否存在差异?系统研究跨系统外推因子。
Biopharm Drug Dispos. 2011 Sep;32(6):303-18. doi: 10.1002/bdd.760. Epub 2011 Jul 4.
10
Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model.清除率体内外外推法中个体间变异性的来源:使用基于机制的群体药代动力学模型预测苯二氮䓬类药物清除率的研究。
Xenobiotica. 2011 Aug;41(8):623-38. doi: 10.3109/00498254.2011.560294. Epub 2011 Mar 24.